{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:13:57Z","timestamp":1790284437461,"version":"4.1.0"},"update-to":[{"DOI":"10.1016\/j.trim.2025.102305","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000}}],"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.trim.2025.102305","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:08:35Z","timestamp":1759792115000},"page":"102305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["WITHDRAWN: Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: A retrospective cohort study"],"prefix":"10.1016","author":[{"given":"Yong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.trim.2025.102305_bb0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.trim.2025.102305_bb0010","series-title":"Mayo Clinic Proceedings: 2016","first-page":"101","article-title":"Multiple myeloma: diagnosis and treatment","author":"Rajkumar","year":"2016"},{"issue":"17","key":"10.1016\/j.trim.2025.102305_bb0015","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.trim.2025.102305_bb0020","first-page":"1323","volume":"61","author":"Roussel","year":"2020","journal-title":"Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma."},{"issue":"27\u201328","key":"10.1016\/j.trim.2025.102305_bb0025","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"issue":"9","key":"10.1016\/j.trim.2025.102305_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.trim.2025.102305_bb0035","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbmt.2017.03.012","article-title":"In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study","volume":"23","author":"Sanchez","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.trim.2025.102305_bb0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","article-title":"FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.trim.2025.102305_bb0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-023-00837-3","article-title":"Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL","volume":"13","author":"Qiu","year":"2023","journal-title":"Blood Cancer J."},{"issue":"23","key":"10.1016\/j.trim.2025.102305_bb0050","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood.V126.23.1996.1996","article-title":"Autologous hematopoietic stem cell transplantation overcomes primary refractory disease in multiple myeloma patients treated with novel agents","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trim.2025.102305_bb0055","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood-2018-99-112790","article-title":"Efficacy of maintenance therapy following auto-HSCT depending on MRD status in patients with multiple myeloma","volume":"132","author":"Solovev","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.trim.2025.102305_bb0060","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10068","key":"10.1016\/j.trim.2025.102305_bb0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.trim.2025.102305_bb0070","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.trim.2025.102305_bb0075","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.trim.2025.102305_bb0080","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.trim.2025.102305_bb0085","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.trim.2025.102305_bb0090","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin. Lymphoma"},{"issue":"5","key":"10.1016\/j.trim.2025.102305_bb0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY","volume":"77","author":"Birgeg\u00e5rd","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.trim.2025.102305_bb0100","first-page":"1159","article-title":"Correlation of IgG levels at initial diagnosis with clinical efficacy and prognosis in 66 patients with IgG multiple myeloma","volume":"27","author":"Nian","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.trim.2025.102305_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blad\u00e9","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"9758","key":"10.1016\/j.trim.2025.102305_bb0110","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.trim.2025.102305_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.trim.2025.102305_bb0120","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1038\/bcj.2014.55","article-title":"Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis","volume":"4","author":"Lu","year":"2014","journal-title":"Blood Cancer J."},{"issue":"22","key":"10.1016\/j.trim.2025.102305_bb0125","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du my\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.trim.2025.102305_bb0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/bjh.17488","article-title":"No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and\/or t(4;14) over the two past decades","volume":"194","author":"Chalopin","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.trim.2025.102305_bb0135","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.trim.2025.102305","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000}}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:36:15Z","timestamp":1760675775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327425001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"alternative-id":["S0966327425001339"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102305","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102305"}}